On Friday, Specialty healthcare company Opko Health Inc. announced that it had decided to terminate its late-stage trial of Bevasiranib for the treatment of wet age-related macular degeneration.

Opko Health said although preliminary data show activity of Bevasiranib when used adjunctively with Genentech’s Lucentis, review of the data by the Independent Data Monitoring Committee indicated the trial was unlikely to meet its primary endpoint.

Opko Health indicated it would continue development of siRNA portfolio targeting Vascular Endothelial Growth Factor or VEGFA, including its VEGFA165b sparing siRNA.

Read ^[1] the full press release on RTT News